Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
MDxHealth Reports Q2 and Half Year 2024 Results
Posted: August 22, 2024 at 2:32 am
MDxHealth Reports Q2 and Half Year 2024 Results
Read more here:
MDxHealth Reports Q2 and Half Year 2024 Results
Posted in Global News Feed
Comments Off on MDxHealth Reports Q2 and Half Year 2024 Results
SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX®
Posted: August 22, 2024 at 2:32 am
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced a new contract with the U.S. Department of Defense (DOD) for the procurement of approximately $9 million of TPOXX® (Contract number: W911SR24C0030). This award is comprised primarily of oral TPOXX®, with a small amount of intravenous (IV) TPOXX®, and represents the third procurement contract award from the DOD over the past three years.
Read more here:
SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX®
Posted in Global News Feed
Comments Off on SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX®
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
Posted: August 22, 2024 at 2:32 am
Vancouver, Canada, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received a new patent approval from the United States Patent and Trademark Office, marking another significant advancement in its proprietary MEAI-based binge behavior regulator program.
Read more from the original source:
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
Posted in Global News Feed
Comments Off on Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
Certara to Participate in Upcoming Investor Conferences
Posted: August 22, 2024 at 2:32 am
RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
Follow this link:
Certara to Participate in Upcoming Investor Conferences
Posted in Global News Feed
Comments Off on Certara to Participate in Upcoming Investor Conferences
Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility
Posted: August 22, 2024 at 2:32 am
Certification Emphasizes Unwavering Commitment to Quality and Is an Essential Step for U.S. Clinical Market Entry Certification Emphasizes Unwavering Commitment to Quality and Is an Essential Step for U.S. Clinical Market Entry
Read the original:
Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility
Posted in Global News Feed
Comments Off on Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility
Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of…
Posted: August 22, 2024 at 2:32 am
Advancing Pharmaceutical Innovation: Brains Bioceutical’s CEP Certification will Streamline Cannabinoid Drug Development, Inspired by Jazz Pharmaceuticals’ CBD-Based Epilepsy Drug and 2024 $1.4 Billion Revenue Projection Advancing Pharmaceutical Innovation: Brains Bioceutical’s CEP Certification will Streamline Cannabinoid Drug Development, Inspired by Jazz Pharmaceuticals’ CBD-Based Epilepsy Drug and 2024 $1.4 Billion Revenue Projection
Read this article:
Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of...
Posted in Global News Feed
Comments Off on Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of…
Bavarian Nordic Announces First Half 2024 Results
Posted: August 22, 2024 at 2:32 am
COPENHAGEN, Denmark, August 22, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first half of 2024 and released its financial calendar for 2025.
Go here to see the original:
Bavarian Nordic Announces First Half 2024 Results
Posted in Global News Feed
Comments Off on Bavarian Nordic Announces First Half 2024 Results
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Posted: August 14, 2024 at 2:37 am
Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to available TKIs
Read the rest here:
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Posted in Global News Feed
Comments Off on Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
Posted: August 14, 2024 at 2:37 am
– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis –
Read the original:
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
Posted in Global News Feed
Comments Off on Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
Posted: August 14, 2024 at 2:37 am
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML –
Go here to read the rest:
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
Posted in Global News Feed
Comments Off on Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
